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ABSTRACT 
 
Drug resistant (DR) tuberculosis (TB) is a rapidly emerging health problem in the Republic of South 
Africa (RSA). Multidrug resistant TB attracts a great deal of scientific attention not only worldwide but 
also in RSA, however, mono- and polyresistant TB is a relatively under studied disease entity. This 
study explored the demographics and characteristics of the types of mono- and polyresistant TB 
groups, and tried to determine if there were any associations between type of TB resistance and 
treatment outcome. The cohort studied consisted of 194 patients who had attended the Helen Joseph 
Hospital TB Focal Point. There were five major types of DR TB identified, including rifampicin (RIF) 
monoresistant (34%, 66 patients), isoniazid (INH) monoresistant (32.5%, 63 patients), INH 
polyresistant (20.1%, 39 patients), RIF polyresistant (4.6%, 9 patients) and phenotypically sensitive TB 
(8.9%, 17 patients). 
 
A concerning figure of 86.6% of the DR TB cohort tested HIV positive, compared to the national 
population where 10.2% are reported HIV positive. The median CD4 was 67 cells/mm
3
, and 30.4% of 
the HIV positive patients had a CD4 count of less than 50 cells/mm
3
. Only 36.6% of the HIV positive 
patients were on antiretroviral therapy at time of DR TB diagnosis. Neither serum albumin nor 
haemoglobin were found to be significant markers for the prediction of outcome in DR TB, and no 
significant differences in DR TB type nor outcome were found when looking at age groups and gender. 
Although the numbers were small RIF monoresistant TB emerged as the most common type of DR TB 
(34%), and as such represents a clinical entity that should be considered separately from MDR TB. 
Unfortunately due to small sample sizes, no significant interpretation could be made regarding the 
various subgroups of DR TB and the genetic mutations to understand if there are differences in clinical 
presentation, mortality and morbidity predictors and outcome, and this is a field that requires further 
investigation. 
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Chapter 1: INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Introduction 
 
Tuberculosis (TB) is a disease caused by Mycobacterium tuberculosis that has plagued mankind since 
antiquity. Discovered by Robert Koch in 1882, TB has since been found globally (Seung et al., 2004). 
TB “remains the leading single cause of death due to an infectious agent throughout the world” 
(Ramaswamy et al., 2003). The burden of disease is prominent in Africa (Vashishtha, 2009), and 
together with the HIV epidemic, is wreaking havoc on the health of many (Chakroborty, 2011). Anti-
tuberculosis drugs have been in use for over half a century, yet the mortality remains high 
(Cattamanchi et al., 2009).  Contributing to this situation is the prolonged treatment period, with 
accompanying poor compliance, inadequate chemotherapy (either due to incorrect prescribing, 
inadequate drug doses, poor compliance, poor absorption of the drugs) emerging drug resistance, the 
HIV epidemic and poor social circumstances (Cox et al., 2007). Transmission from a patient with 
resistant TB plays a major role in spread and development of multi-drug resistant TB (MDR TB), 
whereas acquisition of resistance seems to be the more important factor in development of 
monoresistant TB (Van Rie et al., 2000). 
 
Drug resistant TB (DR TB) is a growing concern, and in the Republic of South Africa (RSA), issues 
exist regarding diagnosis, treatment and prevention (Hafkin, Gammino, & Amon, 2010). Of concern, 
20% of TB cases globally are drug resistant (DR) in some form, with 5.3% being MDR (Jagielski, 
Augustynowicz-Kopec, Zozio, Rastogi, & Zwolska, 2010). A WHO report from 2011 gave South 
African figures as 1.8% of new cases of TB are MDR TB, and 6.7% of retreatment cases are MDR TB 
(WHO, 2011). 
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1.2 Definition 
 
Monoresistance in TB occurs when the organism is exposed to a single drug, either as monotherapy, or 
in a regimen that is inappropriate or failing, creating an effective single drug pressure (Sandman, 
Schluger, Davidow, & Bonk, 1999). Streptomycin was the first drug described to which TB became 
resistant, and this resulted from the use of streptomycin as monotherapy for TB (Gillespie, 2002).  
 
Resistance can occur as either primary or a secondary, where primary drug resistance is found in a 
patient who has never received anti tuberculosis treatment, and secondary drug resistance is found in a 
patient either during or following treatment for previously sensitive TB. Primary drug resistance can be 
outbreak or non-outbreak related, and it is important to differentiate between the two, as outbreak 
associated primary drug resistance has a seemingly worse prognosis, as described in a case series from 
a hospital in Johannesburg , South Africa (Sacks, Pendle, Orlovic, Blumberg, & Constantinou, 1999). 
Primary drug resistance is becoming more common, and is a cause for concern, requiring drug 
sensitivity testing (DST) at diagnosis, rather than after treatment failure (Victor et al., 2007). 
Monoresistant TB is resistance to one of the first-line anti tuberculosis drugs (i.e., isoniazid, 
rifampicin, pyrazinamide, ethambutol, or streptomycin). Poly drug resistant TB is resistance to two or 
more of the first-line anti-tuberculosis drugs, but not both isoniazid and rifampicin. 
 
Data gathered includes laboratory findings of haemoglobin and serum albumin. The value used as cut-
offs in this study for haemoglobin is according to WHO, with severe anaemia defined as a serum 
haemoglobin of less than 8g/dL (World Health Organisation, 2011). The serum albumin cut-off of 
2.0g/L was arbitrary. 
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1.3 Drugs and drug resistance 
 
The two drugs used in both the intensive phase and continuation phase of treatment are rifampicin 
(RIF) and isoniazid (INH). Resistance to these drugs has implications for treatment and outcome, and it 
is thought that resistant TB has a poorer outcome than sensitive TB (Caminero, Sotgiu, Zumla, & 
Migliori, 2010). 
 
RIF is an antibiotic that inhibits deoxyribonucleic acid (DNA)-dependent ribonucleic acid (RNA) 
polymerase. Resistance occurs due to a missense mutation in the rpoB region (Campbell et al., 2001). 
RIF affects slowly metabolizing organisms, and consequently sterilizes the sputum (Gillespie, 2002). 
RIF is the foundation of anti-tuberculosis therapy, in that regimens that do not contain this drug have to 
be administered for a longer period of time and often include injectable drugs on a daily basis, an 
uncomfortable regimen that may lead to decreased compliance. This is one of the reasons why RIF 
monoresistance is a clinical problem (Sandman et al., 1999). 
 
The most important risk factor for RIF monoresistant, as with INH resistance, is previous exposure to 
anti-tuberculosis drugs (Kuaban, Bercion, Jifon, Cunin, & Blackett, 2000; Ridzon et al., 1998). 
Diarrhoea has also been reported to contribute to development of RIF resistance, by contributing to 
malabsorption (Ridzon et al., 1998). Rif monoresistance has been associated with co-infection with 
HIV. Sandman et al suggest that there is potential for drug interactions with anti-retroviral therapy 
(ART) and anti TB treatment, creating selective drug pressures (Sandman et al., 1999). However, there 
are as yet no reports of decreases in TB treatment efficacy when administered with ART. The 
particular interactions described are those between RIF and protease inhibitors, and RIF and non-
nucleoside reverse-transcriptase inhibitors (McIlleron, Meintjes, Burman, & Maartens, 2007).  
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Mutations in the rpoB region are associated with RIF resistance (Chakroborty, 2011), although true 
RIF monoresistance has previously been documented as being relatively uncommon and is often used 
as a marker for MDR TB (Evans, Stead, Nicol, & Segal, 2009).  
 
INH is an antibiotic with a number of mechanisms of action, the main and best understood of which is 
inhibition of mycolic acid synthesis. Other mechanisms include disruption of DNA, lipid, nicotinamide 
adenine dinucleotide (NAD) and carbohydrate metabolism (Zhang & Yew, 2009). The major risk 
factor for developing INH resistance appears to be previous treatment with anti-tuberculosis drugs 
(Cattamanchi et al., 2009) and (Fox et al., 2011), although, unlike RIF monoresistant, INH 
monoresistance does not seem to be induced by interactions with ART  (Hoopes, Kammerer, 
Harrington, Ijaz, & Armstrong, 2008). Different mutations are known to confer differing levels of 
resistance, for example, katG confers high level resistance, whilst inhA confers only low level 
resistance (Gillespie, 2002). It is therefore important to know the mutation in the organism in order to 
predict the level of resistance. 
 
Some studies have suggested that some INH resistance genes may weaken the virulence of the TB 
bacillus, possibly improving clinical outcome in those patients with INH monoresistant TB 
(Cattamanchi et al., 2009). However, another study, conducted in the Western Cape province of South 
Africa (RSA) showed no association between INH resistance and outcome (Jacobson et al., 2011), 
although it did suggest poorer outcome for both sensitive TB and INH resistant TB in RSA than in 
Europe and USA.  The prevalence of INH  monoresistance has been reported in some parts to be 7% 
such as the United States of America (Hoopes et al., 2008), 8-9% in the United Kingdom (Maguire et 
al., 2011) and 2.7% amongst both new and retreatment cases in RSA (Weyer, Brand, Lancaster, Levin, 
& van der Walt, 2007). The lower reported levels of INH resistance among TB isolates in RSA are 
perhaps as a result of poorer reporting due to limited diagnostic testing. INH monoresistance is a cause 
for concern as it has been implicated as an initial event in the development of multi-drug resistant TB 
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(Hazbon et al., 2006). Resistance associated with the Beijing genotype strain shows particular 
predilection for development of further drug resistance (Cox et al., 2007). The Beijing genotype strain 
has been associated with an increase in resistant TB in RSA (Johnson et al., 2010).  
 
INH resistance has been associated with several mutations, including katG and inhA (Chakroborty, 
2011). INH monoresistance is associated with different mutations from multi-drug resistance, in that 
monoresistance is associated with inhA mutations, and multi-drug resistance being more frequently 
associated with katG. The katG gene codes for catalase peroxidase, an enzyme involved in the 
conversion of the prodrug INH to an active form of the drug. The inhA gene codes for enoyl-ACP 
reductase, an enzyme needed in the synthesis of mycolic acid (Hazbon et al., 2006). 
 
Several other mutations have been identified, but clinical significance remains to be proven. 
Furthermore, some INH resistant strains “do not contain mutations in any known gene targets for INH 
resistance” (Hazbon et al., 2006), suggesting that other mutations implicated in conferring INH 
resistance remain to be found (Ramaswamy et al., 2003). 
 
Ethambutol (EMB) is another first line drug, and resistance to it is often associated with resistance to 
INH (A. Jain et al., 2008). This is associated with inhA mutations, where a mutation in the RNA 
polymerase gene confers INH and EMB resistance (Chakroborty, 2011). Another mutation conferring 
EMB resistance is embB (Amita Jain et al., 2008; A. Jain et al., 2008). In a study from the Western 
Cape, RSA, surveillance done on resistant mutants revealed 50% to be EMB resistant (Hoek, Schaaf, 
Gey van Pittius, van Helden, & Warren, 2009). 
 
Pyrazinamide (PZA) is the final drug used in first line therapy. It is a pro-drug that functions best in an 
acidic environment. Monoresistance to PZA has been described in Quebec, Peru, Poland and the 
Western Cape, RSA, all with pncA mutations (Louw et al., 2006) and (Napiorkowska, Augustynowicz-
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Kopec, & Zwolska, 2010). However, PZA resistance is usually associated with MDR TB, with some 
studies quoting 91% PZA resistant mutants to also be resistant to INH and RIF (Louw et al., 2006). In 
another study from the Western Cape, RSA, 53.5% of drug resistant isolates were found to also be 
PZA resistant (Hoek et al., 2009). This finding is similar to a national study in RSA which shows 
52.1% resistant strains also resistant to PZA (Mphahlele et al., 2008).  This is concerning as PZA is 
often relied upon in second line therapy. DST for PZA is not often carried out as it is technically 
challenging, as the acidic environment in which PZA optimally works inhibits bacterial growth. Also, 
the variety of mutations in the pncA gene makes a molecular based technique of resistance 
identification difficult. For these reasons, PZA resistance is not often tested and is possibly under-
reported. 
 
Conducting genotypic and/or phenotypic drug sensitivity testing (DST) on TB is important because it 
allows treatment to be tailored according to the sensitivity pattern, resulting in a better clinical response 
(Thomsen, Bauer, Lillebaek, & Glismann, 2000).  DST at TB diagnosis would avoid amplification of 
resistance, a situation where resistant populations of the TB bacilli are selected as a result of poor drug 
pressure due to a regimen to which the TB is resistant (Cox et al., 2007). This is particularly important 
in areas where there is a high level of pre-existing DRTB, and is well demonstrated by a study 
conducted in Central Asia, where it was shown that 17% of patients with poly-resistant TB developed 
MDR TB, and 7% of patients with existing MDR TB developed further resistance to first line drugs 
through administration of standard first line treatment without initial DST (Cox et al., 2007). 
 
1.4 Tests for resistance 
 
The current gold standard for testing presence of TB and resistance of TB is a specimen culture. Two 
other molecular tests were used in this study population, the Xpert, and the HAIN. 
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Xpert MTB/RIF® Test (Xpert) is a test used to identify TB DNA. In a study conducted in 
Johannesburg, the sensitivity of the Xpert test was 86%, comparing favourably with smear microscopy 
(59%), and in HIV positive individuals, the sensitivity only dropped to 84% for the Xpert. The 
specificity was more than 97% (Scott et al., 2011). Xpert was introduced in the TB Focal Point at HJH 
in an experimental capacity on extra pulmonary fine needle aspirate specimens from July 2010, and 
HJH began performing Xpert on sputum specimens in March 2011. As such, not all the patients in the 
cohort had access to the test. 
 
A molecular assay for the detection of Mycobacterium tuberculosis complex, GenoTypeMTBDRplus 
HAIN Lifescience (HAIN) was also used in this study population. The HAIN test identifies the rpoB 
genetic mutation for RIF resistance, and either the katG or the inhA genetic mutation for INH 
resistance. The sensitivity of the HAIN test is 98.1% for RIF resistance, and 90.2% for INH resistance, 
with specificities of 97.8% for RIF and 100% for INH resistance (Hillemann, Rusch-Gerdes, & 
Richter, 2007).  
 
1.5 Epidemiology 
 
TB is a major concern in RSA, with RSA placing third globally regarding overall TB burden, and a 
prevalence increasing by 400% (SANAC, 2012).  In a study conducted in Swaziland, a country within 
South African borders, the rates of DR TB among culture positive patients for the period 2009 - 2010 
have been reported as around 15% and 49% for new and previously treated patients respectively 
(Sanchez-Padilla et al., 2012). A study conducted amongst miners in the North West province of RSA 
between 2003-2005 showed a rate of 4.3% DR TB, of those, 10.2% had INH resistance, 5.6% 
polyresistant, and 84.4% MDR TB (Calver et al., 2010). In a survey from 2007, RSA, any type of DR 
TB occurred in 7.7% of patients, with INH monoresistance being found in 2.6% of new treatment 
cases, and 2.9% in retreatment cases. RIF monoresistant was found in 0.2% new cases and 0.8% 
19 
 
retreatment cases. Overall, monoresistant TB (either RIF, INH, streptomycin, EMB) was found in 
5.1% of all cases (Weyer et al., 2007). 
 
 
It is difficult to comment on the prevalence of mono- and polyresistant TB and outcome of treatment, 
in RSA, with more of the studies focusing on MDR TB. It would be interesting to know whether 
mono- and polyresistant TB have an effect on outcome, and what the risk factors associated with DR 
TB are.  
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Chapter 2: METHODOLOGY 
 
2.1 Aims and objectives 
 
It is the aim of this retrospective analysis to review and describe the database on mono- and 
polyresistant TB cases treated at TB Focal Point at Helen Joseph Hospital (HJH) which is a public 
hospital in Johannesburg, Gauteng province, RSA, and services many surrounding clinics and 
geographical areas. TB Focal point deals specifically with drug resistant TB and with difficult to treat 
TB. We seek to comment on the proportion of mono- and polyresistant TB, making associations with 
risk factors and resistance profiles, and looking at outcomes in these groups. 
 
The primary objective of this study was to review and describe the cohort of patients with mono- and 
polyresistant TB from the database at TB Focal Point at HJH, for the period 1st March 2009 to 31st 
December 2011. 
 
The secondary objectives were as follows: 
 
2.1.1 To determine the proportion of patients with RIF monoresistance and describe the mutations 
present in this group 
2.1.2 To determine the proportion of patients with INH monoresistance and describe the mutations 
present in this group 
2.1.3 To determine the proportion of patients with poly-resistant TB 
2.1.4 To look at the association between patient characteristics and treatment outcome 
2.1.5 To describe treatment outcomes for the above groups 
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2.2 Study population 
 
This study is a retrospective description of the database for the period 1st March 2009 to 31st 
December 2011, of patients who presented with DR TB to TB Focal Point. TB Focal Point is a 
specialised clinic dealing specifically with drug resistant TB. Patients could be diagnosed at TB Focal 
Point or were referred by local TB clinics after detection of DR TB. The database had 270 patients, and 
included data on demographics, laboratory specimens that confirmed the diagnosis, and information on 
treatment and outcome.  
 
2.3 Data collection 
 
Any patient in the database who had a result showing genotypic mono- or polyresistant TB was 
included. Conversely, in those with no results for either RIF or INH resistance, that patient’s 
information was excluded. Duplicate entries were removed from the data, and patients less than 18 
years of age were excluded. During the review of the database, 39 patients were found to have MDR 
TB, and were thus excluded. Similarly, three patients were found to have XDR TB and were excluded. 
Eight patients had genotypically drug sensitive (DS) TB and were excluded as they were on the 
traditional drug sensitive treatment regimen. Twelve patients had missing information about resistance 
and were excluded. This left 194 patients for analysis. 
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Chart 1. Patient Selection 
 
 
The data was captured from the existing database using a data collection sheet (Appendix 1). 
Outstanding laboratory information was sought through National Health Laboratory Services (NHLS). 
Paper files held at TB Focal Point were assessed to update and complete the database for any missing 
clinical information. 
 
Treatment outcomes could be: cured; treatment completed; died; failed; defaulted; or transferred out. 
The definitions of the treatment outcomes are based upon the national TB guidelines from RSA (Dept 
of Health, 2014). Cure for RIF monoresistant TB is defined as a patient who has completed treatment 
according to program protocol for 18 months after culture conversion and has at least five consecutive 
negative cultures from samples collected at least 30 days apart in the final 12 months of treatment. 
Cure for INH monoresistant TB is defined as a patient who has completed treatment according to 
program protocol for 6 months after culture conversion and has at least five consecutive negative 
cultures from samples collected at least 30 days apart in the final 12 months of treatment. Sputum 
conversion is defined as two negative sputum samples at least thirty days apart. If only one positive 
= 194 patients for analysis 
-12 No Drug Sensitivity testing 
-8 Genotypically Drug Sensitive TB 
-3 XDR TB 
-39 MDR TB 
-3 Age <18 y 
-11 Duplicate entries 
270 patients on Database 
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culture is reported during that time, and there is no concomitant clinical evidence of deterioration, a 
patient may still be considered cured, provided that this positive culture is followed by a minimum of 
three consecutive negative cultures taken at least 30 days apart. Treatment will be considered to have 
failed if two or more of the five cultures recorded in the final 12 months of therapy are positive, or if 
any one of the final three cultures is positive (Dept of Health, 2014).   
 
2.4 Data analysis and statistics 
 
The analysis is based on 194 cases provided, and while not all cases had complete information, the 
analysis is based on the original sample. 
 
All analysis was carried out using IBM SPSS version 21 software. Χ2 and Fisher’s exact test were used 
to compare proportions. Variables associated with DR TB were re-examined by a logistic regression 
model. 
 
2.5 Ethical approval 
 
The research proposal has been approved by the WITS Human Research Ethics Committee, M120434.
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Chapter 3: RESULTS 
 
3.1 General characteristics of sample population: 
 
The median age of the sample population was 34.5 years of age (SD ±10.0). Of the sample group, 
71.6% of the patients were in the age group of 18-39; 25.3% of the patients in the age group 40-59; 
with 3.1% of the patients in the age group above 60 years of age. Sex of the patients in the sample was 
fairly even, with 49% male and 51% female. From the available data, 26% of the patients were in 
employment, while 40.2% of the patients were not in employment. A total of 130 cases were valid for 
analysis, representing 67.2% of the total dataset, leaving 33.8% unknown. No data on type of 
employment was included, as a precursor to the type of employment and predisposition to DR TB. 
 
Graph 1: Graphical representation of age groups of the cohort 
 
 
 
The median haemoglobin was 9.9 g/dL (SD ± 2.5).  Data ranges from a minimum of 3.8 g/dL to 15.6 
g/dL. A total of 120 cases were valid for analysis, representing 61.9% of the total dataset. 
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A haemoglobin of less than 8 g/dL was found in 14.4% of the cases, while 47.9% of the sample had a 
haemoglobin of more than 8 g/dL.  
 
The serum albumin had a median of 2.2 g/L (SD ± 0.71). The range of albumin was minimum 1.2 g/L 
to maximum 4.2 g/L. A serum albumin of less than 2.0 g/L was found in 23.2% of the patients, while 
36.1% of the patients had a serum albumin of more than 2.0 g/L.  
 
A startling 86.6% of the patients were HIV positive; 8.8% of the patients HIV negative and in 4.6% of 
the patients the HIV status was unknown. A median CD4 count of 63 cells/mm
3
 was obtained for the 
sample, with a minimum value of 1 cells/mm
3 
and a maximum value of 930 cells/mm
3
. The lower 
quartile is 30.5 and upper quartile is 145.5, with an interquartile range of 115. A CD4 count of less than 
50 cells/mm
3 
was found in 30.4% of the cases, while 26.3% of the patients a CD4 count of 50-199 
cells/mm
3
, 9.3% a CD4 count of 200-349 cells/mm
3
; and 5.7% a CD4 count of more than 350 
cells/mm
3
.  
 
Of the patients who were HIV positive, 36.6% were on ART, 26.8% of the patients were not on ART 
and 36.6% of the patients had no data on whether or not they were on ART. A total of 194 cases were 
valid for interpretation. 
 
The median weight at diagnosis was 54 kg (SD ± 10.0). A total of 131 cases were valid, representing 
67.5% of the total dataset. The median weight at end of treatment was 62.2 kg (SD ± 10.5). A total of 
89 cases were valid for analysis, representing 45.9% of the total dataset. 
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Chart 2: Percentage of major TB types 
  
 
 
 
  
Major TB Types 
Rifampicin mono resistant TB
Isoniazid mono resistant TB
Isoniazid poly resistant TB
Rifampicin poly resistant TB
Genotypically resistant,
phenotypically sensitive TB
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Table 1: Characteristics of sample population per DR TB group: 
 Rifampicin 
monoresista
nt TB 
N = 66 
Isoniazid 
monoresistant 
TB 
N = 63 
Isoniazid 
polyresistant 
TB 
N = 39 
Rifampicin 
polyresistant 
TB 
N = 9 
Phenotypically 
sensitive 
N = 17 
Age groups: p < 0.05 p < 0.05 p > 0.05 p < 0.05 p > 0.05 
18 – 39 years 45/66 
(68.2%) 
47/63 (74.6%) 26/39 (66.7%) 8/9 (88.9%) 13/17 (76.5%) 
40 – 59 years 21/66 
(31.8%) 
13/63 (20.6%) 10/39 (25.6%) 1/9 (11.1%) 4/17 (23.5%) 
>60 years 0/66 (0%) 3/63 (4.8%) 3/39 (7.7%) 0/9 (0%) 0/17 (0%) 
Sex: p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 
Male 31/66 (47%) 34/63 (54%) 18/39 (46.2%) 4/9 (44.4%) 8/17 (47%) 
Female 35/66 (53%) 29/63 (46%) 21/39 (53.8%) 5/9 (55.6%) 9/17 (53%) 
Employment: p < 0.05 p < 0.05 p < 0.05 p < 0.05 p < 0.05 
Yes 18/66 
(27.3%) 
15/63 (23.8%) 13/39 (33.3%) 3/9 (33.3%) 3/17 (17.6%) 
No/unknown 48/66 
(72.7%) 
48/63 (76.2%) 20/39 (66.7%) 6/9 (66.7%) 14/17 (82.4%) 
HIV status: p < 0.05 p < 0.05 p < 0.05 p < 0.05 p < 0.05 
Positive 59/66 
(89.4%) 
55/63 (87.3%) 31/39 (79.5%) 8/9 (88.9%) 15/17 (88.2%) 
Negative 4/66 (6.1%) 5/63 (7.9%) 7/39 (17.9%) 1/9 (11.1%) 0/17 (0%) 
Unknown 3/66 (4.5%) 3/63 (4.8%) 1/39 (2.6%) 0/9 (0%) 2/17 (11.8%) 
Anti-
retroviral 
therapy (of 
the patients 
with HIV): 
N = 59 N = 55 N = 31 N = 8 N = 15 
Yes 18/59 
(30.3%) 
19/55 (34.5%) 11/31 (35.4%) 3/8 (37.5%) 5/15 (33.3%) 
No 41/59 
(69.7%) 
36/55 (65.5%) 20/31 (64.5%) 5/8 (62.5) 10/15 (66.7%) 
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The table below is a break-down per CD4 class as specified in the dataset. The procedure was to 
analyse the major type of TB per CD4 class within the dataset, and then an analysis was performed to 
understand if there is a significant difference between the classes and the types of TB. There were 137 
patients with data available for CD4 count. 
 
Table 2: CD4 class per TB type 
 
 
  
Drug resistant 
TB Type  
No. of patients 
with CD4 < 50 
(%)  
n = 59/137 
No. of patients 
with  CD4  50 – 
199 (%) 
n = 51/137 
No. of patients 
with  CD4  200 – 
350 (%) 
n = 21/137 
No. of patients with  
CD4 > 350 (%) 
 
 n = 11/137 
Isoniazid  
monoresistant 
28 (20.4%) 16 (11.7%) 3 (2.2%) 2 (1.5%) 
Isoniazid 
polyresistant 
10 (7.3%) 15 (10.9%) 7 (5.1%) 3 (2.2%) 
Rifampicin 
monoresistant 
17 (12.4%) 17 (12.4%) 11 (8.0%) 6 (4.4%) 
Rifampicin 
polyresistant 
3 (2.2%) 3 (2.2%) 0 (0%) 0 (0%) 
Genotypically 
resistant, 
phenotypically 
sensitive 
1 (0.7%) 0 (0%) 0 (0%) 0 (0%) 
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Table 3: Type of specimen retrieved from patients  
 
Type of Specimen Percentage of patients with specimen retrieved 
(%)  
Sputum 62.9 
Blood 14.4 
Fine needle aspirate 5.7 
Fine needle aspirate and Sputum 3.1 
Pus and Fine needle aspirate 2.6 
Pleural fluid 2.1 
Pus 1.5 
Cerebro spinal fluid 1.5 
Ascites 1 
Blood, Pus and Fine needle aspirate 1 
Blood and Ascites 1 
Sputum, Fine needle aspirate and blood 1 
Sputum and Bone Marrow 0.5 
Blood and Cerebro spinal fluid 0.5 
Sputum, Blood and Ascites 0.5 
Sputum, Cerebro spinal fluid and Pleural fluid 0.5 
 
 
A total number of 193 cases out of the 194 cases in the sample population were valid for analysis for 
Xpert MTB/RIF® Test (Xpert), representing 99.5% of the total sample. A positive Xpert result was 
found in17% of the patients, 9.3% of the patients had a negative Xpert, and 73.2% of the patients did 
not have an Xpert done or the result was unknown. Of the patients with an Xpert result, 22.2% of the 
patients had RIF Resistance. A total of 49 cases were valid for analysis, representing 25.3% of the total 
sample. 
 
Initial sputum microscopy was performed on 77.3% of the patients, while 22.7% of the patients did not 
have a microscopy of the initial sputum sample done. A total of 194 cases were valid for analysis, 
representing 100% of the sample population. Of the patients who had microscopy performed, 43.3% 
had a positive microscopy for acid fast bacilli (AFB), while 34% of the patients had negative AFB 
microscopy. A total of 150 cases were valid for analysis, representing 77.3% of the total dataset. 
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Initial sputum culture was performed on 95.4% of the patients, while 3.6% did not have a culture done.  
Of those patients who had a culture performed, 92.8% of the patient’s culture results indicated positive 
for TB, while 2.6% of the patient’s culture results were negative for TB. The remainder had unknown 
results, and information regarding contamination of the specimen not being known. 
 
Graph 2: Comparison of TB test performed 
 
 
 
A molecular assay for the detection of Mycobacterium tuberculosis complex, GenoTypeMTBDRplus 
HAIN Lifescience, was performed on 76.8% of the patients, while 23.2% of patients did not have this 
test performed. At the time of the study, there was no protocol in place for the routine use of HAIN, 
and as such, specimens would undergo HAIN testing as an initial test if specifically requested by the 
treating doctor, otherwise, the HAIN was performed on culture positive specimens. Of all patients in 
which a genotypic drug sensitivity result was obtained, 43.3% of the patients were sensitive to INH; 
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32.5% of the patients were resistant to INH; and in 1% of the patients genotypic drug sensitivity testing 
to INH failed. No patients exhibited INH genotypic susceptibility testing as unknown. 
 
Of all patients with a drug sensitivity result obtained by molecular testing, 37.6% of the patients 
exhibited sensitivity to RIF; 35.6% of patients resistant to RIF; 3.1% of patients unknown; and in 0.5% 
of patients drug sensitivity testing to RIF by the molecular assay failed.  
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Graph 3: Graphical representation of genotypic drug susceptibility test results 
Graph 3 indicates the results from the HAIN testing, where 76.8% of the samples underwent a HAIN 
test. Of those samples that underwent the test, the proportion of resistance is shown in the graph. The 
total adds up to more than 100% as some samples could have both INH and RIF resistance. 
 
 
 
Genotypic susceptibility testing revealed a mutation in 61.9% of the patients, while for 38.1% the 
mutation was unknown. A phenotypic DST was conducted in73.7% of the patients, while 26.3% of the 
patients did not have a phenotypic DST done. A total of 194 cases representing 100% of the dataset 
were valid for analysis. 
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Chart 3: Percentage of mutation combinations in cohort 
 
 
 
Combination 1: rpoB wild type 8 missing; no mutation, katG wild type missing, mutation 1 present, 
inhA wild type 2 missing; mutation 3b present  
Combination 2: rpoB wild type 7 missing; no mutation, katG wild type missing; mutation present, 
inhA wild type 2 missing; mutation 3b present   
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3.2: RIF monoresistant TB 
 
RIF monoresistant TB has the largest representation in terms of proportion of patients with TB .Of 
these patients, 4.5% were cured; 16.6% of the patients completed treatment; 9.1% of the patients died; 
1.5% of the patients had treatment that failed; 13.6% of the patients defaulted on treatment; 9.1% of the 
patients were transferred out; 13.6% of the patients were still on treatment; 1.5% of patients were lost 
to follow-up; and 30.3% of patient’s had files that were not retrievable. 
 
Table 4: RIF monoresistant TB outcomes in various countries 
 
Country, (total 
number cohort) 
Cured, or 
treatment 
completed 
Died Lost to 
follow up, 
files not 
retrievable, 
transferred 
out 
Relapsed Still on 
treatment 
Other (defaulted 
treatment, 
stopped,failed) 
France 
(Meyssonnier, Bui, 
Veziris, Jarlier, & 
Robert, 2014) (30) 
67% 
(n=20) 
10% 
(n=3) 
13% (n=4) 10% (n=3)   
Saudi Arabia 
(Singla, Al-Sharif, 
Al-Sayegh, Osman, 
& Shaikh, 2002) 
(18) 
88% 
(n=16) 
  11.11% 
(n=2) 
  
South Africa, our 
findings (34) 
21.2% 
(n=14) 9.1% 
(n=6) 
40.9% 
(n=27) 
 13.6% 
(n=9) 
15.1% (n=10) 
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If one removes the cases where the files were not retrievable, lost to follow up cases, and the cases that 
were transferred out, where the outcomes are not known, and are not necessarily poor, the new 
denominator total would be 39. In this case, the outcome for RIF monoresistance would be as follows. 
 
Table 5: RIF monoresistant TB outcomes excluding cases with unknown outcomes 
 
Outcome Cured/treatment 
completed 
Died Failed 
treatment/defaulted 
Still on treatment 
Number of 
cases/39 (%) 
14 (35.9) 6 (15.4) 10 (25.6) 9 (23.1) 
 
Of the 34% of patients that had RIF monoresistant TB, 70.9% of these patients the mutations that were 
known, while 29.1% of these patients the mutations were not known.  
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Table 6: Mutations present and percentage in the RIF monoresistant TB group 
Genetic mutation Percentage of patients with 
mutation 
rpoB 6/7/8 missing, no mutation,  
no katG mutation ,  
inhA no gene locus 
1.5 
rpoB 6/8 missing, no mutation,  
no katG mutation,  
no inhA mutation 
1.5 
rpoB intense wild type 7, light wild type 8,  
no katG mutation,  
no inhA mutation 
1.5 
rpoB wild type 2 dark, wild type  missing, with no mutations,  
no katG mutation,  
no inhA mutation 
7.6 
rpoB wild type 4/5 missing, no mutation,  
no katG mutation,  
no inhA mutation 
3.0 
rpoB wild type 6 missing, no mutation,  
no katG mutation,  
no inhA mutation 
1.5 
rpoB wild type 6/7/8 missing, no mutation,  
no katG mutation,  
no inhA mutation 
1.5 
rpoB wild type 7 missing, mutation 2B present,  
no katG mutation,  
no inhA mutation 
3.0 
rpoB wild type 7 missing, mutation 2A present,  
no katG mutation,  
no inhA mutation 
13.6 
rpoB wild type 7 missing, mutation 2B present,  
no katG mutation,  
no inhA mutation 
3.0 
rpoB wild type 7 missing, no mutation,  
no katG mutation,  
no inhA mutation 
4.5 
rpoB wild type 7 missing, no mutation,  
no katG mutation,  
inhA mutation 
4.5 
rpoB wild type 8 missing, mutation 3 present,  
no katg mutation, 
no inhA mutation 
22.7 
rpoB wild type 9 missing, mutation 3 present,  
no katG mutation,  
no inhA mutation 
1.5 
 
 
Unknown / not recorded 29.3 
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3.3: INH monoresistant TB 
 
Isoniazid (INH) monoresistant TB had the second largest representation in terms of proportion of 
patients with DR TB. Of the 32.5% of patients that had INH monoresistant TB, 3.2% were cured; 
20.6% of the patients completed treatment; 6.3% of the patients died; 6.3% of the patients had 
defaulted on treatment; 27.0% of the patients were transferred out; and 36.5% of the patients files were 
irretrievable. 
 
Of the 32.5% of patients that had INH monoresistant TB, 47.7% of these patients the mutations that 
were known, while 52.3% of these patients the mutations were not known or not recorded.  
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Table 7: Mutations present and percentage in the INH monoresistant TB group 
 
Genetic mutation Percentage of patients with 
mutation 
no rpoB mutation,  
katG wild type missing, mutation present,  
no inhA mutation 
3.2 
no rpoB mutation,  
katG wild type missing, mutation  present,  
no inhA mutation 
1.6 
no rpoB mutation,  
no inhA mutation, 
katG wild type missing, mutation present 
1.6 
no rpoB mutation,  
no katG mutation,  
inhA wild type missing, mutation present 
1.6 
no rpoB mutation,  
no kat katG g mutation,  
inhA wild type1 missing, mutation present 
12.7 
no rpoB mutation,  
no katG mutation,  
inhA wild type 2 missing, mutation 3B present 
1.6 
no rpoB mutation,  
katG wild type missing, mutation present,  
no inhA mutation 
22.2 
rpoB wild type 2 missing, no mutation,  
no katG mutation,  
no inhA mutation 
1.6 
rpoB wild type 8 missing, mutation 3 present,  
no katG mutation,  
no inhA mutation 
1.6 
Unknown / not recorded 52.3 
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3.4: Polyresistant TB 
 
There were 20.1% of the patients who had INH polyresistant TB; and 4.6% of the patients were RIF 
polyresistant TB. In the group of polyresistant TB, 3.6% had INH and EMB resistance; 2.6% had RIF 
and EMB resistance; 1.5% had RIF and streptomycin resistance; 0.5% had one of the following groups 
of resistance each: INH, streptomycin, EMB, ofloxacin, kanamycin; INH, EMB, ethionamide, 
streptomycin, PZA; INH, streptomycin, ethionamide; INH, streptomycin, PZA; RIF, ethionamide; or 
INH, EMB, ethionamide, and streptomycin resistance. 
 
3.4.1 INH polyresistant TB 
 
There were 20.1% (39 patients) with INH polyresistant TB. Of these patients, 7.7% were cured; 15.4% 
of patients completed treatment; 5.1% died; 35.9% of patients were transferred out; 2.6% of patients 
were still on treatment, 2.6% of patients were still on treatment; and 30.8% of patient’s files were 
irretrievable. Mutations were known in 74.4%, while 25.6% had mutations that were not known or not 
recorded. 
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Table 8: Mutations present and percentage in the INH polyresistant TB group 
 
Genetic mutation Percentage of patients with 
mutation 
No rpoB mutation,  
katG wild type missing, mutation present,  
No inhA mutation 
2.6 
No rpoB mutation,  
katG wild type missing, mutation present 
inhA wild type missing and mutation present 
5.1 
No rpoB mutation,  
no katG mutation, 
inhA wild type missing, mutation present 
30.8 
No rpoB mutation,  
katG wild type missing, mutation present  
No inhA mutation 
25.6 
rpoB wild type 2/3 missing, no mutations,  
no katG mutation, 
No inhA mutation 
2.6 
rpoB wild type 7 missing, no mutation,  
katG wild type missing, mutation present,  
inhA wild type 2 missing, mutation 3B present 
2.6 
rpoB wild type 7 dark wild type 8, no mutations  
katG wild type missing, mutation present,  
inhA wild type 2 missing, mutation 3B present 
2.6 
rpoB wild type 8 missing, no mutations  
katG wild type missing, mutation present,  
inhA wild type 2 missing and mutation 3B present 
2.6 
Unknown / not recorded 25.6 
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3.4.2: RIF polyresistant TB 
 
There were 4.6% of patients that had RIF polyresistant TB, of which 11.1% completed treatment; 
22.2% of patients had died; 44.4% of patients with RIF polyresistant TB defaulted on treatment; 11.1% 
of patients were transferred out; and 11.1% of patient’s files were not retrievable. 
 
In 66.7% of patients the mutations were known, whilst the remainder of the mutations were not known, 
or not recorded. 
 
Table 9: Mutations present and percentage in the RIF polyresistant TB group 
 
Genetic mutation Percentage of patients with 
mutation 
rpoB wild type 3/4 missing, no mutation,  
no katG mutation,  
No inhA mutation 
11.1 
rpoB wild type 6 missing, no mutation,  
no katG mutation,  
No inhA mutation 
11.1 
rpoB wild type7 missing, mutation 2A present,  
no katG mutation,  
No inhA mutation 
11.1 
rpoB wild type7 missing, mutation 2A present,  
no katG mutation,  
No inhA mutation 
11.1 
rpoB wild type 7 missing, mutation 2B present,  
no katG mutation,  
No inhA mutation 
11.1 
rpoB wild type 8 missing, mutation 3 present,  
no katG mutation and  
No inhA mutation 
11.1 
Unknown / not recorded 33.4 
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3.5: Genotypically resistant, phenotypically sensitive TB 
 
These were patients who were Xpert RIF resistant, or resistant on testing with GenoTypeMTBDRplus 
HAIN Lifescience, but DST sensitive. These patients had been initiated on drug resistant TB therapy 
initially according to Xpert or HAIN results, but DST for first line TB drugs later proved 
phenotypically sensitive TB. The phenotypically sensitive group represented 8.8% (17) of all the 
patients. In this group, 5.9% of patients were cured, 23.5% of patients completed treatment, 5.9% of 
patients had treatment failed, 5.9% of patients had treatment defaulted, 41.2% were transferred out, 
5.9% of patients were still on treatment, and 11.8% of patients files were not retrievable. Of the 8.8% 
of patients that were in the sensitive group, 53.1% of patients the mutations were known. 
 
Table 10: Mutations present and percentage in the drug sensitive TB group 
 
Genetic mutation Percentage of patients with mutation 
rpoB wild type 1 missing, no mutation,  
No inhA mutation,  
no katG mutation 
5.9 
rpoB wild type 1/8 missing, no mutation,  
no katG mutation,  
No inhA mutation 
5.9 
rpoB wild type 2 missing, no mutations,  
no katG mutation,  
No inhA mutation 
11.8 
rpoB wild type 2/3 missing, wild type 3/4 missing, no 
mutations,  
no katG mutation,  
No inhA mutation 
5.9 
rpoB wild type 3/4 missing, no mutation,  
no katG mutation,  
No inhA mutation 
5.9 
rpoB wild type 7 missing, no mutation,  
no katG mutation,  
No inhA mutation 
11.8 
rpoB wild type 8 missing, no mutation,  
no katG mutation,  
No inhA mutation 
5.9 
Unknown / not recorded 46.9 
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3.6 Treatment outcomes and factors predicting outcomes 
 
Table 11: Treatment outcome of sample population 
 
Treatment Outcome % of patients n = 194 
File not retrievable 58 (29.9%) 
Transferred Out 45 (23.2%) 
Treatment complete 35 (18%) 
Treatment defaulted 18 (9.3%) 
Died 14 (7.2%) 
Still on treatment 11 (5.7%) 
Cured 9 (4.6%) 
Treatment failed 2 (1%) 
Lost to follow-up or treatment stopped 1 (0.5%) 
 
The below analysis is based on the CD4 class and the type of outcome recorded.  
 
Table 12: Representation of CD4 class and treatment outcome 
 
Treatment 
Outcome 
No. of patients 
with CD4 < 50 
(%) 
No. of patients 
with CD4 50-199 
(%) 
No. of patients 
with CD4 200-
349 (%) 
No. of patients with 
CD4 > 349 (%) 
Cure 1 (0.7) 3 (2.2) 1 (0.7) 1 (0.7) 
Treatment 
completed 9 (6.6) 
12 (8.8) 4 (2.9) 4 (2.9) 
Died 6 (4.4) 5 (3.7) 1 (0.7) 0 (0) 
Treatment 
failed 
1 (0.7) 0 (0) 0 (0) 1 (0.7) 
Treatment 
defaulted 
6 (4.4) 1 (0.7) 4 (2.9) 0 (0) 
Transferred 
out 
9 (6.6) 11 (8.0) 4 (2.9) 2 (1.5) 
Still on 
treatment 
3 (2.2) 4 (2.9) 1 (0.7) 0 (0) 
Lost to 
follow up 
0 (0) 0 (0) 0 (0) 0 (0) 
Treatment 
stopped 
0 (0) 0 (0) 0 (0) 0 (0) 
File not 
retrieved 
24 (17.5) 15 (11.0) 3 (2.2) 3 (2.2) 
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The analysis below indicates the treatment outcomes per albumin class. A T-test to understand if 
significant differences occur between the groups in addition to tests of association that were computed 
to indicate if there is a practical output that can be used. The analysis is based on 115 valid cases for 
albumin.  
 
Table 13: Representation of albumin class and treatment outcome 
 
Treatment Outcome No. of patients with  
Albumin < 2.0 g/L (%) 
No. of patients with  
Albumin > 2.0 g/L (%) 
Cure 1 (0.9) 5 (4.4) 
Treatment completed 7 (6.1) 16 (13.9) 
Died 7 (6.1) 4 (3.5) 
Treatment failed 0 (0) 1 (0.9) 
Treatment defaulted 4 (3.5) 6 (5.2) 
Transferred out 7 (6.1) 11 (9.6) 
Still on treatment 2 (1.7) 4 (3.5) 
Lost to follow up 0 (0) 1 (0.9) 
Treatment stopped 0 (0) 1 (0.9) 
File not retrieved 17 (14.8) 21 (18.3) 
 
No significant differences or associations were found between the 2 groups, thus indicating that 
albumin is not a predictor for treatment outcome (P>0.05). 
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The analysis below indicates the treatment outcomes per Haemoglobin class. A paired T-test to 
understand if significant differences occur between the groups as well as tests of association was 
computed to indicate if there is a practical output that can be used. The analysis is based on 120 valid 
cases for Haemoglobin. 
 
Table 14: Representation of haemoglobin class and treatment outcome 
 
Treatment Outcome No. of patients with 
Haemoglobin < 8 g/dL (%) 
No. of patients with 
Haemoglobin > 8 g/dL (%) 
Cure 1 (0.8) 3 (2.5) 
Treatment completed 6 (5) 17 (14.5) 
Died 4 (3.3) 6 (5) 
Treatment failed 0 (0) 1 (0.8) 
Treatment defaulted 2 (1.7) 9 (7.5) 
Transferred out 6 (5) 18 (15) 
Still on treatment 1 (0.8) 5 (4.2) 
Lost to follow up 0 (0) 1 (0.8) 
Treatment stopped 0 (0) 1 (0.8) 
File not retrieved 8 (6.7) 32 (26.7) 
 
No significant differences or associations were found between the 2 groups, thus indicating that 
haemoglobin is not a predictor for treatment outcome. 
 
In order to test the change in weight at the beginning and end of the treatment for significance, a T-test 
for one sample was computed at a 95% of confidence interval. This test indicates if there is a difference 
between the groups mean weights at the end and beginning of the treatment. The analysis was based on 
a sample size of 131 patients at the beginning and 89 at the end.  A two-tailed test was performed as a 
difference in weight was being tested in either direction from the mean. The mean weight at the 
beginning was 54.6 kg, with a standard deviation of 10.1, while the weight at the end had a mean of 
61.6 kg, with a standard deviation of 10.5. Statistically there is a significant difference (p<0.05) 
between the weights at the beginning and at the end of the treatment. There is thus an indication that 
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weight increases significantly after the treatment, however, ART remains a confounding factor. No 
data on date of initiation of ART was available, and as such, the increase in weight cannot solely be 
attributed to the treatment of TB. 
 
Table 15: Representation of outcome per TB type 
 
Outcome Rifampicin  
monoresistant 
TB % 
 
 
 
N = 66 
Isoniazid 
monoresistant 
TB % 
 
 
 
N = 63 
Rifampicin 
polyresistant 
TB  % 
 
 
 
N = 9 
Isoniazid 
polyresistant 
TB % 
 
 
 
N = 39 
Genotypically 
resistant, 
phenotypically 
sensitive TB 
% 
 
N = 17 
Cure 4.5 3.1 0 7.7 5.8 
Treatment 
Completed 
16.6 20.6 11.1 15.9 23.5 
Died 9.1 16.3 22.2 5.1 0 
Treatment failed 1.5 0 0 0 5.8 
Defaulted 13.6 6.3 44.4 0 5.8 
Transferred out 9.1 27.0 11.1 35.9 41.7 
Still on 
treatment 
13.6 0 0 2.6 5.8 
Lost to follow 
up 
1.5 0 0 0 0 
File not 
retrieved 
30.3 36.5 11.1 30.7 11.8 
 
Unfortunately, the majority of the cases had outcomes that were not quantifiable, in that they were not 
necessarily poor outcomes, (ie, death or treatment failure), but neither could they count as a good 
outcome (ie cure, treatment completed), making statistical analysis non-significant, as total numbers 
were too small. 
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Chapter 4: DISCUSSION 
 
4.1 General overview 
 
In a retrospective analysis we reviewed and described the cohort of patients with mono- and 
polyresistant TB treated at TB Focal Point at HJH. Our study population’s mean age was older (34.5 
years ± 10.7) than the rest of RSA (25 years) and Gauteng (28 years) (StatsSA, 2011). Our study found 
71.6% of patients were between the ages of 18 years and 39 years, in keeping with many other studies 
showing that DR TB is more frequently found in the third and fourth decade (Coovadia, Mahomed, 
Pillay, Werner, & Mlisana, 2013; Dalton et al., 2012; Farazi et al., 2013; Hang et al., 2013). The 
younger age may be confounded by the relatively recent development of resistant strains, and spread of 
said strains. 
 
One multicentre study, which included South African data, showed that in all countries they studied, 
DR-TB was more common in men than women (Dalton et al., 2012). There have been other differences 
found between sexes regarding DR TB, namely, fluoroquinolone resistance and XDR have been found 
more commonly in women than men (Dalton et al., 2012). Also, in a South African study it was shown 
that the ratio of confirmed TB cases was 2.1:1, female to male (Austin, Dick, & Zwarenstein, 2004). 
This was a study on TB, and not particularly DR TB, but does suggest that a gendered incidence of TB 
exists, however, no significant difference in gender was found in our study. The gender breakdown is 
what would be expected from a South African population, but may be representative of the catchment 
area around the HJH as well. This is in keeping with several other studies which showed no significant 
difference between sex and DR TB (Farazi et al., 2013; Kuaban et al., 2000). 
 
The official unemployment rate in RSA was 25.2% for the first quarter of 2013. The expanded 
unemployment rate was 36,7% in the first quarter of 2013 – the highest since 2008. Our finding of 
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40.2% unemployed patients is in keeping with the South African statistics, but is considerably less than 
the 67.6% found in South African MDR-TB patients in a recent study (Dalton et al., 2012). A 
European (Faustini, Hall, & Perucci, 2006) study showed no increased risk of MDR TB with 
unemployment, and although our study was looking at mono- and polyresistant TB, our findings are in 
keeping with those of the European study. 
 
Unfortunately, this study did not have access to data regarding the type of employment of those 
patients who were employed, as this might have shown a pattern of drug resistance. It has been shown 
in other studies that DR TB is increased in miners in RSA (Talbot et al., 2003). 
 
The median haemoglobin concentration of 9.95 g/dL (SD ± 2.47) is higher than that found in a 
Mozambican study where the median haemoglobin concentration was 8.1 g/dL in DR TB patients, and 
7.8 g/dL in DS TB patients (Nunes et al., 2005). 14.4% of the cohort had severe anaemia, a 
haemoglobin of less than 8g/dL. The difference is most likely not due to the resistance patterns of the 
TB as both MDR and sensitive TB patients had lower median haemoglobins than our patient cohort. 
The increased burden of malaria could possibly cause the observed lower haemoglobin in the 
Mozambican study.  
 
The median serum albumin of the cohort was 2.2 g/L (SD ± 0.71), with 23.2% of patients having a 
serum albumin less than 2.0 g/L. Although the serum albumin did not correlate with any particular 
outcome nor the TB type in this study, the values demonstrated in this study are lower than those 
described in a Turkish study (Sahin & Yildiz, 2013). However, the Turkish cohort was not HIV 
positive, so a direct comparison is not reliable. Furthermore, our study does not have adequate data on 
comorbidities, for example malnutrition, chronic gastro enteritis, chronic inflammation, or liver 
problems, and, due to this confounding factor, we cannot  draw any significant conclusions as to 
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whether serum albumin may be lower in DR TB than in DS TB. This is an area of possible future 
research.   
 
Of the cohort, 86.6% were HIV positive, with a median CD4 of 67 cells/mm
3
 (SD 134.1), and 56.7% of 
cases with a CD4  below 200 cells/mm
3
. The low CD4 count found is in keeping with Nunes et al 
(Nunes et al., 2005), who described a cohort of HIV positive patients, showing that DR TB 
predominantly had a CD4 less than 100 cells/mm
3
. There was no significant difference seen amongst 
the groups of patients regarding HIV reactivity, although the proportion of patients with HIV far 
outweighed those without HIV (86.6% of the patients were HIV positive and 8.8% were HIV 
negative). The presence of HIV did not predispose patients to a certain type of DR TB, nor predict an 
increase in a particular outcome, in keeping with various other studies from Botswana, Iran and RSA 
(Churchyard, Corbett, Kleinschmidt, Mulder, & De Cock, 2000; Farazi et al., 2013; Kuaban et al., 
2000). However, the total number of patients who were HIV negative was small, and should significant 
inference like to be made regarding increased risk in patients with or without HIV, a larger sample of 
HIV negative patients would be needed. Only 36.6% of patients were on ART at the time of diagnosis 
of DR TB. There was no data regarding the percentage of patients started on ART after diagnosis of 
DR TB had been made following arrival at the TB Focal Point. This is in contrast to data from Malawi, 
reporting that 74% of the TB cohort studied in Lilongwe were co-infected with HIV, and 64% were on 
ART at the time of presentation (Vorkas et al., 2012). The high HIV prevalence found in this study 
(86.6%), accompanied by the low CD4 on admission to the TB Focal Point, suggests advanced HIV 
disease, and this demonstrates  a need to improve linkage to HIV care with better documentation of 
ART initiation.  
 
In order to understand if there was a difference between the CD4 count and the type of TB an 
independent T-Test was computed at a 95% confidence interval. While the numbers indicate that there 
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is a difference, statistically there is no difference (p>0.05) between the CD4 count and the type of TB. 
This indicates that CD4 count cannot be used as a predictor of the type of TB. These results may not be 
consistent with what is seen in practice, but based on the sample, CD4 count is not a predictor (no 
associations) of type of DR TB.  
A study conducted in Cameroon (Kuaban et al., 2000) showed that 59.6% of their patients had 
resistance to more than one drug, but their study included MDR patients, whereas our study excluded 
MDR and XDR TB. Our study found 24.7 % patients in the cohort had polyresistant TB, the difference 
possibly being accounted for by the exclusion of MDR patients. 
Other studies have demonstrated repeatedly that the most significant risk factor for DR TB is prior 
treatment for TB (Dalton et al., 2012; Kuaban et al., 2000). Unfortunately, our database did not contain 
adequate information on previous treatment, and this parameter was not assessed. 
Another variable we did not look at was geographical area. Dalton et al. found that resistance to second 
line injectable agents was more frequently found in Eastern Cape than in other provinces of RSA 
(Dalton et al., 2012). This is an important point to consider, as outbreaks could be localized, and 
having knowledge on local resistance patterns could help in suspecting and adequately managing DR 
TB patients prior to DST availability. 
 
An interesting observation from our study was that the group with sensitive TB had a higher HIV 
positivity rate (88.2%) than the general population. A possible explanation being that HIV is a 
predisposition to TB. There were 35.3% of the sensitive TB group with HIV co-infection who were 
already on ART at the time of TB diagnosis, comparing favourably to the general population. 
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It was also noticed that the weight of patients increased with treatment of their DR TB, with a mean 
weight at the start of therapy of 54.5kg (SD 10.1kg) and at the end of treatment mean weight 61.6kg 
(SD 10.4kg). This is in keeping with recovery from a chronic illness. 
 
This study demonstrated poor documentation of several factors, including type of therapy initiated, 
date of change of therapy, sputum testing on a monthly basis to follow up on treatment and cure rates, 
and there was poor archiving at this health facility. This suggests a need to improve documentation at 
patient visits, and a better archiving system. However, this study was conducted before the 
employment of a full time data capturer, which will hopefully resolve this issue. A suggestion that the 
health facility involves an infectious disease physician or a TB expert in the treatment of DR TB at the 
clinic level could also alleviate these problems. 
 
4.2 RIF monoresistant TB 
 
In studies conducted in Cameroon and Mozambique, it was found that RIF resistance was always 
associated with INH resistance, resulting in MDR TB (Kuaban et al., 2000; Nunes et al., 2005). In 
another study, conducted in Free State, South Africa, it was found that 2.5% (5/196) of DR TB patients 
had RIF monoresistance, with most RIF resistance occurring in the presence of MDR TB (Churchyard 
et al., 2000). RIF monoresistant TB was the most common TB type found in the study. Whilst RIF 
resistance has been regarded as a proxy for MDR TB, our study found that the largest group of 
resistance amongst our DR TB patients was RIF monoresistance, suggesting that the correlation 
between RIF monoresistance and MDR TB may not be as reliable as once thought. The increased 
frequency of RIF monoresistance has been reported by three other South African studies (Coovadia et 
al., 2013; Dramowski et al., 2012; Mukinda et al., 2012). In this study, we did not look at the 
correlation between genotypic and phenotypic testing regarding RIF monoresistance as a marker for 
MDR TB, however, as we report such a high number of RIF monoresistance, we suggest that 
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diagnoses of RIF resistant TB made by genotypic methods be confirmed by culture and sensitivity 
methods also, as outlined by the South African National Department of Health TB guidelines. 
 
Our study found no significant difference between the sexes at a 95% significance level (p>0.05), in 
contrast to that described by Coovadia et al (Coovadia et al., 2013) reporting that males had a 42% 
increased odds of RIF monoresistant TB than females.  
 
There is a significant difference (p<0.05) between patients with RIF monoresistant TB and HIV status, 
however caution should be heeded when interpreting that HIV positive patients are more prone to 
monoresistant TB, as the sample of HIV positive patients far exceeds the HIV negative patients, thus 
should an inference based on HIV status want to be made, a larger HIV negative sample is required. 
That said, there is still evidence that HIV patients are more susceptible to monoresistant TB. This is in 
keeping with Vietnamese data, reporting that HIV co-infection is a risk factor for RIF monoresistant 
TB (Hang et al., 2013). Of interest is that previous ART treatment may predispose to development of 
RIF monoresistant TB (Mukinda et al., 2012), and although this point was not addressed in the current 
study, it has important implications for the future. 
 
Alcohol abuse has also been reported in RSA as a risk factor for RIF monoresistance (Mukinda et al., 
2012), but was unfortunately not included in the data base the current study analysed. 
 
The phenotypically sensitive group had rpoB mutations, or were missing the wild type, and had no 
katG nor inhA mutations. This group was genotypically resistant, but tested phenotypically sensitive 
on DST. It is possible that this group represents subclinical RIF resistance, and is an area of further 
research and attention. 
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Our data does not compare favourably with international data regarding cure or treatment completed 
for RIF monoresistant TB, however, the outcome may be affected by the large number of files not 
retrievable (30%) and by those patients still on treatment at the end of the study period (13%). 
Furthermore, 9% of patients were transferred to another care facility and no further information was 
traced. 
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4.3 INH monoresistant TB 
 
INH monoresistant TB was found to be the second largest representation (32.5%) in terms of 
proportion of patients with resistant TB in our study. This was comparable to the 33% of patients with 
INH monoresistant TB in a study conducted in Cameroon (Kuaban et al., 2000), and the 29% in the 
cohort studied in Vietnam after excluding MDR (Hang et al., 2013). A study reported 15% INH 
monoresistance in Mozambique (Nunes et al., 2005) and a staggering 68.4% amongst DR-TB (this 
study included primary and acquired DR-TB) in a South African study conducted between the years 
1993-1997 (Churchyard et al., 2000). The large number of patients with INH monoresistance seen in 
the Churchyard et al study could be accounted for by the study population, miners in Free State, RSA, 
residing in the mine compounds. These living conditions could predispose patients to outbreaks, 
similar to those observed in prisons and other settings where people live in close proximity to one 
another.  
 
Another factor to consider is the inappropriate use of INH prophylaxis in patients who may have 
undetected or undiagnosed TB, resulting in mono-therapy and predisposition to develop resistance. 
Churchyard et al. did state that their study was conducted prior to the use of INH prophylaxis, and 
although not a factor in their study, remains an important consideration. 
 
There was no significant difference between the sexes at 95% significance level, in keeping with many 
other studies on MDR TB (Kuaban et al., 2000).  
 
There is a significant difference (P<0.05) between the age groups of patients with INH monoresistant 
TB, with the majority of patients falling into the 18-39 year group, however these difference, like RIF 
monoresistant TB, cannot be attributed solely to age and therefore interpretation as to the significant 
differences should be done cautiously. 
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Only 23.8% of the INH monoresistant patients were in employment, whilst the remainder were not in 
employment or employment was not recorded. Unfortunately, there was no data on type of 
employment, as a precursor to the predisposition of monoresistant TB. The unemployment rates of 
patients with INH monoresistant TB could be higher than in the general South African population, but 
the analysis is confounded by the number of patients with data missing or not known. 
  
Most patients INH monoresistant TB (87.3%) were HIV positive, 7.9% of the patients were HIV 
negative, while 4.8% of the patients had a HIV status unknown. There is a significant difference          
(P<0.05) between patients with INH monoresistant TB and HIV status. Closely related to the HIV 
status, and the patients with INH monoresistant TB, is ART. Of the patients with INH monoresistant 
TB and HIV, 34.9% were on ART. More than half of patients with DR TB in RSA are co infected with 
HIV (Meintjes, 2014), compared to 4.6% of all TB patients in Israel who are co infected with HIV 
(Zohar, Moshe, Daniel, Noa, & Itamar, 2014), and a range varying from 0% (Slovakia and Slovenia) to 
14.6% (Portugal) of co infection with HIV and TB (Pimpin et al., 2011). Controversy remains in the 
literature as to whether HIV infection is a risk factor for DR TB, with some studies in favour of the 
increased risk (Mesfin, Hailemariam, Biadgilign, & Kibret, 2014) and others not supporting the 
association (Berhan, Berhan, & Yizengaw, 2013). Of the reported 6,422,179 people living with HIV in 
South Africa, 31.2% are on ART as at October 2012 (Shisana et al., 2012). This compares with the 
proportion of patients with INH monoresistant TB and HIV co infection who are on ART at time of 
diagnosis of DR TB. 
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4.4 INH polyresistant TB 
 
Kuaban et al showed that 12.2% of patients with DR TB had INH poly-resistant TB (Kuaban et al., 
2000), comparable with Churchyard et al who showed 11.2% (Churchyard et al., 2000), and Nunes et 
al who showed 15% of patients with DR TB had INH polyresistance (Nunes et al., 2005). Our study 
found 20.1% of patients with INH poly, in keeping with a study from Burundi which described 22% of 
their DR TB being INH poly after excluding MDR TB (Faustini et al., 2006). This difference could be 
accounted for by the exclusion of MDR TB in our study regarding the Kuaban study, but Churchyard 
had 22/196 patients, and Nunes had 3/20 patients with INH poly and not MDR TB. Hang et al reported 
39% of their cohort with DR TB as having INH polyresistance, after excluding MDR TB (Hang et al., 
2013). 
 
4.5 RIF polyresistant TB 
 
Once MDR was excluded, RIF polyresistance was not described in a South African study (Churchyard 
et al., 2000), neither was RIF poly described in Mozambique (Nunes et al., 2005), nor in Vietnam 
(Hang et al., 2013). One patient in a European cohort of  non MDR or XDR DR-TB was found to have 
RIF polyresistant TB (1.1%) (Faustini et al., 2006). 
 
There is a significant difference (P<0.05) between the age groups of patients with RIF poly-resistant 
TB, however these difference cannot be attributed solely to age and therefore interpretation as to the 
significant differences should be done cautiously. 
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Chapter 5: STUDY LIMITATIONS 
 
This study has several limitations.  
 
At the time of the study, DR TB treatment in Gauteng was managed at various hospital levels, 
according to type of resistance. MDR TB was managed at a centralised hospital (Sizwe Hospital), 
while mono- and polyresistant TB were left to being managed at facilities like TB Focal Point, HJH. 
These facilities tasked with managing mono- and polyresistant TB did not have access to all drugs, did 
not have guidance on treatment or protocols, and there was no standardization of regimen or follow-up. 
This resulted in the non-uniformity of treatment, including drug choice and duration, making studies 
such as this one difficult to compare with other centers. Information regarding the initial drug 
treatment, and the potentially revised treatment after resistance result was not available to the study 
investigator. 
 
The study only represents patients who presented to the health care facility, and does not consider the 
patients who have limited or no access to healthcare, and misses patients in whom the diagnosis of TB 
was missed. A panoply of reasons cause diagnostic delay and diagnostic failure including, health 
seeking delay on the patients part, provider failure to diagnose TB, care seeking between sectors and 
poor inter-sectorial communication, and use of the private sector. This can result in patients who 
should be treated in specialised care centres being missed, and thus excluded from adequate treatment, 
follow-up and possibly notification (Skordis-Worrall, Hanson, & Mills, 2010). A selection bias 
therefore exists within our study. 
 
Given our small evaluable sample size, it was difficult to determine any associations between patient 
characteristics and drug-resistance or mortality. 
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Another limitation is the lack of complete data, resulting in a small sample size. This study was 
conducted before a full time clerk had been allocated to the database, and as such, the data is 
incomplete. Tracing old records and patient files is challenging as not all the information is recorded in 
a standardised fashion, and not all the information is available, either through lack of collection from 
the health care provider or from lack of adequate documentation. Data was updated and sought as far 
as possible, but some files were not found and as such, labelled missing. 
 
Patients are down- referred to their local clinics for completion of DR TB treatment once they are 
stable, and are on oral treatment available at the local clinic and are stable. This was a limitation in the 
study as ethical approval had not been obtained to follow the patients up to their point of care at the 
local clinic; therefore many outcomes were missing in the study. 
 
Many patients had results missing for follow up sputum collections. Laboratory reference error and 
tracking may have played a part, but also the down referral of patients made follow up of results 
difficult. This meant that in some cases, the diagnosis of cure could not be made, and the patient had to 
then be classified as treatment completed. Of concern, though, is that the sputum samples may not have 
been collected, representing a breakdown of provider care. 
 
In this study, we did not have access to information regarding the patients past medical history 
regarding previous episodes of TB, and past treatment of TB, as well as information relating to 
adherence history. This is an important factor to consider, as previous treatment of TB was found as 
the only risk factor for acquired DR TB in a study from Cameroon (Kuaban et al., 2000).  
 
We also did not gather information about alcohol use, tobacco use, imprisonment and unemployment, 
all of which are factors associated with increased risk for development of resistance to second line 
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injectable agents (Dalton et al., 2012) and looking for an association in first line treatment may have 
been fruitful. 
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Chapter 6: CONCLUSIONS 
 
RIF monoresistant TB was the largest group in this study, highlighting the presence of RIF 
monoresistant TB as an entity separate to MDR TB. There is concern about the poor outcome of RIF 
monoresistant TB as 24.2% of patients in this study died or defaulted, compared to only 18.1% of 
patients who were cured or completed treatment. There were, however, also 13.6% of patients still on 
treatment at the time of the study completion. Our study showed no clear patient characteristics in 
terms of risk factors for acquisition of RIF monoresistant TB, nor any clear predictors of outcome. The 
most common mutations found in this group were rpoB wild type 8 missing, mutation 3 present 
(22.7%) and rpoB wild type 7 missing, mutation 2A present (13.6%). Unfortunately the numbers were 
too small to assess any differences between the mutations, but this would be an interesting field for 
further research. Given that one quarter of the patients had a bad outcome, RIF monoresistant TB needs 
further study to gain clarity on risk factors and factors affecting outcome in order to improve these 
outcomes. 
 
Our study showed no significant risk factors for INH monoresistant TB, although most patients 
(87.3%), like the other DR TB groups, tested HIV positive. The common mutations found in INH 
monoresistant TB are katG wild type with a mutation (22.2%) and inhA wild type missing, mutation 1 
present (12.7%). Proposed factors influencing INH monoresistant TB include occupation (especially 
mining in RSA), and possibly the prescribing of INH prophylaxis to HIV positive patients who are at 
risk for TB. Another potential risk factor could be outbreak related INH monoresistance. Our study did 
not address these factors but this remains an area for further research.  
The mutations found most commonly in INH polyresistant TB were inhA wild type with mutation 1 
present (30.8%), and katG wild type with mutation (25.6%). The proportion of INH polyresistant TB in 
our study was in keeping with other South African data. 
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In conclusion, RIF monoresistant TB was the most prevalent DR TB type in this cohort and treatment 
outcomes are poor. It is advised to treat any RIF resistant TB according to local MDR TB treatment 
guidelines. This study was unable to identify any predictors for DR TB type and DR TB treatment 
outcome, but research in this area should continue to enable the treating clinician to anticipate and 
aggressively manage patients with predicted poorer outcomes. The geographical pattern of sensitivity 
of TB is important as this could also guide clinicians in treatment selection, particularly in poorly 
resourced areas. Early appropriate treatment could lead to better control of the disease and limit spread 
of DR TB. 
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